Home Newsfeeds Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer Downgrades Relmada Therapeutics to Perform

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

byBenzinga Newsdesk

October 13, 2022

1 minute read

Oppenheimer analyst Jay Olson downgrades Relmada Therapeutics (NASDAQ:RLMD) from Outperform to Perform.

How To Earn $500 A Month From Annaly Capital Management Stock

By Avi Kapoor

December 29, 8:50 AM

Annaly Capital Management, Inc. (NYSE: NLY) shares closed flat on Thursday, despite the S&P 500 hovering near its record closing level, set on Jan. 3, 2022.

NLY

‘Tesla Executives Hold Market Entry Talks With India Investment Agency’ – Reuters News

By Happy Mohamed

July 28, 10:21 AM

https://www.reuters.com/business/autos-transportation/tesla-executives-hold-market-entry-talks-with-india-investment-agency-sources-2023-07-28/ Two senior Tesla executives discussed the company's plans to

INDA

GlucoTrack Announces Preclinical Testing With Implantable Continuous Glucose Monitor

By Benzinga Newsdesk

October 12, 8:37 AM

Glucotrack, Inc. (NASDAQ:GCTK) ("Glucotrack" or the "Company"), a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today that it has achieved another

GCTK

News

Spruce Power Receives Notice Regarding NYSE Continued Listing Standard

By Happy Mohamed

March 31, 4:15 PM

Spruce Power Holding Corp. (NYSE:SPRU) ("Spruce Power" or the "Company"), a leading owner and operator of distributed solar energy assets across the United States, today announced that on March 28,

SPRU

Oppenheimer Downgrades Relmada Therapeutics to Perform

Related Posts

How To Earn $500 A Month From Annaly Capital Management Stock

‘Tesla Executives Hold Market Entry Talks With India Investment Agency’ – Reuters News

GlucoTrack Announces Preclinical Testing With Implantable Continuous Glucose Monitor

Spruce Power Receives Notice Regarding NYSE Continued Listing Standard